Mylan inks agreement with Natco for generic Copaxone

CANONSBURG, Pa. Mylan has signed a license and supply agreement with Natco Pharma for a generic version of Teva’s blockbuster multiple sclerosis drug Copaxone.

Under the terms of the agreement, Mylan will have exclusive distribution rights in the U.S., Europe, Australia, New Zealand, Japan and Canada with an option to expand into other areas. Natco already has commercialized its generic Copaxone (glatiramer acetate) product in India and the Ukraine.

Worldwide sales of the brand drug were more than $1.7 billion in 2007, according to Teva.

The drug has patent protection in the U.S. until 2014.